GENCHLADEATH

Bacterial host cell death modulators – a genetic approach to identify anti-apoptotic factors of Chlamydia trachomatis and to explore their role during infection

Coordinatore	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)    more  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Mrs. Nome: Isabelle Cognome: Verdier Email: send email Telefono: +33 1 48073433 Fax: +33 1 48073426
Nazionalità Coordinatore	France [FR]
Totale costo	268˙329 €
EC contributo	268˙329 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2013-IOF
Funding Scheme	MC-IOF
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-10-01   -   2017-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Mrs. Nome: Isabelle Cognome: Verdier Email: send email Telefono: +33 1 48073433 Fax: +33 1 48073426	FR (PARIS)	coordinator	268˙329.30

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Chlamydia trachomatis is a leading cause of sexually transmitted disease - with reported prevalence rates of up to 17% among asymptomatic women in Europe - and as such a frequent cause of infertility. While these bacteria have been known for more than a decade to protect infected cells from apoptosis, the lack of tools for genetic manipulation of chlamydiae significantly hampered the investigation of underlying molecular mechanisms and their role during infection. Yet, the research group of Dr. Valdivia (outgoing host) has recently established a unique system to perform forward genetics in chlamydiae, and in course of the proposed project Dr. Sixt (the fellow candidate) will be among the first researchers able to learn and exploit these techniques. In this process, she will first recover mutant C. trachomatis strains that display a reduced potential to block apoptosis. This will subsequently enable her to identify bacterial anti-apoptotic factors and to study the significance of Chlamydia-mediated cell death modulation in a murine infection model. Finally, she will assess the effect of interference with the anti-apoptotic trait on the immunogenic potential of dying host cells, based on the detection of specific cellular “immunogenicity predictors” that were recently identified by the group of Dr. Kroemer (European return host). This multidisciplinary investigation will provide invaluable insights into chlamydial virulence and will help to predict whether the anti-apoptotic trait may be a potential new drug target. The project offers Dr. Sixt extensive training that is highly complementary to her previous research experiences. The acquired skills, international experience, and newly established contacts will place her in an excellent position to take a leading role in the further development of this scientific field and will enable her to implement infection biology at the European return host institute, which will further expand the institute’s areas of excellence.'